Cellmat Therapeutics Submits Appeal Against Delisting
[Asia Economy Reporter Lee Junhyung] Cellma Therapeutics announced on the 19th that it has submitted an objection regarding its delisting.
Previously, Cellma Therapeutics received a disclaimer of opinion in the auditor's report for the last fiscal year.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- [Breaking] Samsung Labor-Management 'Performance Bonus Negotiations' Fail in Third Mediation... Union Says "General Strike to Proceed as Planned Tomorrow"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- Bull Market End Signal? Securities Firm Warns: "Sell SK hynix 'At This Moment'"
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
The company stated, "The Korea Exchange will decide on granting an improvement period in accordance with Article 25, Paragraph 5 of the KOSPI Listing Regulations."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
